We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Children’s Hospital Boston Selects HybSelect from febit for Targeted Resequencing
News

Children’s Hospital Boston Selects HybSelect from febit for Targeted Resequencing

Children’s Hospital Boston Selects HybSelect from febit for Targeted Resequencing
News

Children’s Hospital Boston Selects HybSelect from febit for Targeted Resequencing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Children’s Hospital Boston Selects HybSelect from febit for Targeted Resequencing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Molecular Genetics Core Facility (MGCF) at Children’s Hospital Boston chose febit’s HybSelect technology which will enable genetics researchers to conduct economic targeted enrichment of genes of interest for resequencing. In January the core facility will be receiving the Geniom RT Analyzer® from febit to perform HybSelect.

“We feel that febit’s HybSelect technology will be a powerful tool for our researchers, in conjunction with our Applied Biosystems SOLiD platform, at a reasonable cost,” said Hal Schneider, Core Manager of the MGCF. “The ease and flexibility of HybSelect allows us to study a variety of genetic diseases and multiplex bar-coded libraries, making sequence capture projects much more accessible and affordable for our investigators.”

The economy of HybSelect increases the potential for widespread use of next generation sequencing in clinical studies. Instead of sequencing the complete genomes of only a few patients, HybSelect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort.  The larger patient pool now provides the statistically relevant data that are necessary for clinical studies.

Peer Staehler, CSO at febit, said: “Targeted enrichment and multiplexing are necessary to truly benefit from the advantages of high performance sequencers, and febit has developed HybSelect to meet this need. Together with Life Technologies’ SOLiD 3, HybSelect can sequence 16 parallel samples in one run. febit is currently working on an upgrade to a 96-plex barcode set. This will enable sequencing of 2,304 samples in six working days.”
Advertisement